Exploring the therapeutic potential of glucagon-like peptide 1 agonists in metabolic disorders

doi:10.3748/wjg.v31.i4.101436

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 31, Issue 4

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (618)

All Articles published online

The chart showing PDF series, HTML series.

Item

Count

PDF

HTML

535

Sum=549

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=28

Jan 28, 2025 (publication date) through Feb 21, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Letter to the Editor

World J Gastroenterol. Jan 28, 2025; 31(4): 101436
Published online Jan 28, 2025. doi: 10.3748/wjg.v31.i4.101436

Exploring the therapeutic potential of glucagon-like peptide 1 agonists in metabolic disorders

Adrián Cortés-Martín, Julio Plaza-Diaz

Adrián Cortés-Martín, Promoting Fitness and Health Through Physical Activity Research Group, Sport and Health University Research Institute, University of Granada, Granada 18016, Andalusia, Spain

Julio Plaza-Diaz, School of Health Sciences, Universidad Internacional de La Rioja, Logroño 26006, La Rioja, Spain

Author contributions: Cortés-Martín A and Plaza-Diaz J designed the overall concept and outline of the manuscript, reviewed the literature, wrote and edited the manuscript.

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Julio Plaza-Diaz, PhD, School of Health Sciences, Universidad Internacional de La Rioja, Avenida de la Paz 137, Logroño 26006, La Rioja, Spain. julioramon.plaza@unir.net

Received: September 14, 2024
Revised: October 28, 2024
Accepted: November 20, 2024
Published online: January 28, 2025
Processing time: 107 Days and 4.3 Hours

Core Tip

Core Tip: This article comments on the work by Soresi and Giannitrapani concerning glucagon-like peptide 1 agonists as potentially useful drugs to treat metabolic dysfunction-associated steatotic liver disease. The integration of dietary changes and regular physical exercise into treatment may improve patient outcomes. These lifestyle adjustments may reduce the reliance on pharmacological interventions and/or increase the effectiveness of existing treatments. Therefore, lifestyle factors should not be overlooked in the broader strategy to manage metabolic dysfunction-associated steatotic liver disease, since they complement medical therapies.